3Janka HU, Plewe G, Riddle MC,et al. Comparison of basal insulin added to oralagents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes[J]. Diabetes Care,2005; 28 (2) :254-9.
4Jovarovic L, Daily G, Huang WC,et al. Repaglinide in type 2 diabetes: a 24-week ,fixed-dose efficaly and safety study[ J ]. Pharmacology, 2000 ;40 ( 1 ) :49-57.
5Rosenstock J, Dailey G, Massi-Benedetti M, et al. Reduced hypoglycemia risk with insulin glargine:a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes[ J]. Diabetes Care,2005 ;28:950- 95.
6Riddle MC, RosenstockJ, Gerich J, et al. The treat-to-target trail : randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients[ J]. Diabetes Care,2003 ;26:3080-6.
7Dunn CJ,Plosker GL, Keating GM, et al. Insulin glargine:an updated review of its use in the management of diabetes mellitus [ J ]. Drugs,2003; 63 : 1743-78.
8Kurtzhals P, Schaffer L, Sorensen A, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use [ J ]. Diabetes,2000 ;49:999-1005.
9C. A. Gogos,S. Giali,F. Paliogianni,G. Dimitracopoulos,H. P. Bassaris,A. G. Vagenakis. Interleukin-6 and C-reactive protein as early markers of sepsis in patients with diabetic ketoacidosis or hyperosmosis[J] 2001,Diabetologia(8):1011～1014
